SaaS breakthrough QbDVision® claims $15MM Series A to advance digitization of biomanufacturing
Summary
A SaaS solution purpose-built for drug lifecycle management, QbDVision is designed to advance the digital maturity of the industrys chemistry, manufacturing, and controls (CMC) activities. This round of funding brings the total capital raised to $20MM which will drive expansion of a commercial market that already includes a wide range of enterprise pharma, biotech, and CDMO customers across the world. "QbDVision is an exciting platform poised to drive digital transformation in the biopharmaceutical contract manufacturing segment," says Paxton Major, Senior Associate at Northpond Ventures. With QbDVision, CMC teams can now take a structured approach to consolidating their knowledge, integrating their workflows, and curating their data in ways that significantly enhance operational efficiency. QbDVision is the first modern digital CMC workspace: a cloud-based SaaS solution designed to enhance the curation, utilization, and integrity of process development data to accelerate therapies to patients.